HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alice B Gottlieb Selected Research

Prostaglandins A

1/2019Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.
8/2013Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
8/2013Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
10/2012The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
2/2012A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
4/2007An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept.
4/2004Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
6/2003The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison.
5/2003Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alice B Gottlieb Research Topics

Disease

165Psoriasis (Pustulosis Palmaris et Plantaris)
05/2022 - 05/2002
57Psoriatic Arthritis
07/2022 - 09/2003
25Infections
01/2022 - 11/2003
15Neoplasms (Cancer)
12/2021 - 12/2005
8Inflammation (Inflammations)
08/2018 - 12/2002
6Metabolic Syndrome (Dysmetabolic Syndrome X)
02/2021 - 01/2008
6Pain (Aches)
01/2018 - 10/2010
5Arthritis (Polyarthritis)
01/2022 - 01/2006
5Necrosis
01/2018 - 02/2009
5Skin Diseases (Skin Disease)
10/2016 - 05/2003
5Atopic Dermatitis (Atopic Eczema)
10/2016 - 08/2005
5Rheumatoid Arthritis
01/2016 - 01/2004
5Skin Neoplasms (Skin Cancer)
07/2015 - 12/2008
4Ankylosing Spondylitis
04/2022 - 01/2012
3Body Weight (Weight, Body)
05/2022 - 01/2008
3Vitiligo
01/2022 - 06/2017
3Tuberculosis (Tuberculoses)
12/2021 - 05/2007
3Pruritus (Itching)
11/2020 - 04/2016
3Cardiovascular Diseases (Cardiovascular Disease)
12/2014 - 01/2008
3Autoimmune Diseases (Autoimmune Disease)
04/2013 - 05/2007
2Injection Site Reaction
12/2021 - 01/2012
2Hyperlipidemias (Hyperlipidemia)
02/2021 - 08/2011
2Hypertension (High Blood Pressure)
02/2021 - 08/2011
2Obesity
02/2021 - 08/2011
2Acne Vulgaris
11/2020 - 03/2004
2Hidradenitis Suppurativa
06/2020 - 08/2016
2Pyoderma Gangrenosum
11/2016 - 11/2012
2Dermatomyositis (Dermatopolymyositis)
11/2016 - 11/2008
2Nasopharyngitis
10/2016 - 09/2015
2Nail Diseases (Nail Disease)
12/2012 - 05/2007
2Allergic Contact Dermatitis
03/2012 - 11/2006
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2012 - 11/2010
2Tetanus
06/2010 - 11/2003

Drug/Important Bio-Agent (IBA)

35Biological ProductsIBA
02/2022 - 11/2002
29Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2019 - 12/2002
27Etanercept (Enbrel)FDA Link
05/2022 - 11/2003
24Monoclonal AntibodiesIBA
01/2022 - 11/2002
24Ustekinumab (CNTO 1275)FDA Link
01/2021 - 06/2010
19Infliximab (Remicade)FDA Link
01/2021 - 01/2003
17Tumor Necrosis Factor InhibitorsIBA
01/2019 - 11/2003
16secukinumabIBA
05/2022 - 09/2013
14CytokinesIBA
01/2020 - 11/2002
10apremilastIBA
02/2021 - 03/2012
10Adalimumab (Humira)FDA Link
01/2020 - 07/2006
10efalizumab (Raptiva)FDA Link
07/2006 - 05/2002
9InterleukinsIBA
04/2022 - 06/2010
9Pharmaceutical PreparationsIBA
02/2021 - 06/2003
9Methotrexate (Mexate)FDA LinkGeneric
06/2020 - 01/2008
9Prostaglandins AIBA
01/2019 - 05/2003
9Alefacept (Amevive)FDA Link
09/2011 - 11/2003
8Cyclosporine (Ciclosporin)FDA LinkGeneric
02/2020 - 08/2003
8Interleukin-12 (IL 12)IBA
06/2014 - 12/2004
7Immunoglobulin A (IgA)IBA
05/2022 - 03/2016
7guselkumabIBA
02/2022 - 01/2018
7Interleukin-17 (Interleukin 17)IBA
11/2020 - 11/2014
7C-Reactive ProteinIBA
11/2020 - 08/2013
7Adrenal Cortex Hormones (Corticosteroids)IBA
02/2020 - 05/2003
6Interleukin-23 (Interleukin 23)IBA
02/2022 - 01/2012
5bimekizumabIBA
07/2022 - 08/2018
5tildrakizumabIBA
05/2022 - 01/2020
5Biomarkers (Surrogate Marker)IBA
01/2014 - 07/2008
4ixekizumabIBA
04/2022 - 09/2018
4Proteins (Proteins, Gene)FDA Link
10/2006 - 11/2002
3ruxolitinibIBA
01/2022 - 06/2017
3Antirheumatic Agents (DMARD)IBA
01/2021 - 05/2014
3Mycophenolic Acid (Cellcept)FDA LinkGeneric
06/2020 - 09/2009
3Hydroxyurea (Hydrea)FDA LinkGeneric
06/2020 - 11/2008
3Tacrolimus (Prograf)FDA LinkGeneric
06/2020 - 08/2005
3Leflunomide (Arava)FDA LinkGeneric
06/2020 - 09/2009
3AcitretinFDA Link
02/2020 - 07/2007
3omega-Chloroacetophenone (Mace)IBA
10/2017 - 12/2014
3Immunoglobulins (Immunoglobulin)IBA
10/2010 - 04/2006
3RetinoidsIBA
01/2008 - 07/2005
3Immunoglobulin G (IgG)IBA
01/2006 - 11/2002
2Interleukin-23 Subunit p19IBA
02/2022 - 01/2020
2FumaratesIBA
06/2020 - 09/2009
2Thioguanine (Tioguanine)FDA Link
06/2020 - 09/2009
2Certolizumab PegolFDA Link
08/2018 - 01/2018
2Abatacept (Orencia)FDA Link
09/2017 - 02/2015
2ametantrone (HAQ)IBA
12/2016 - 06/2014
2InterferonsIBA
11/2016 - 12/2009
2Messenger RNA (mRNA)IBA
08/2015 - 05/2007
2golimumabFDA Link
07/2014 - 05/2010
2Phosphodiesterase 4 InhibitorsIBA
04/2013 - 03/2012
2tazarotene (Tazorac)FDA Link
09/2011 - 11/2002
2Immunomodulating AgentsIBA
11/2010 - 08/2003
2AntigensIBA
06/2010 - 09/2003
2Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
01/2008 - 06/2005
2ChemokinesIBA
05/2007 - 10/2006
2Interleukin-8 (Interleukin 8)IBA
05/2007 - 08/2005
2pimecrolimus (Elidel)FDA Link
09/2005 - 11/2004

Therapy/Procedure

61Therapeutics
01/2022 - 05/2003
12Biological Therapy
05/2022 - 11/2002
10Phototherapy (Light Therapy)
02/2020 - 12/2009
3Immunomodulation
11/2010 - 04/2003
3Immunotherapy
01/2004 - 01/2003
2Subcutaneous Injections
01/2020 - 01/2008
2Excimer Lasers
09/2019 - 01/2012
2Aftercare (After-Treatment)
10/2016 - 06/2008
2Oral Administration
01/2012 - 10/2008